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Educationa b s t r a c t
Even though rabies is almost uniformly fatal, it is readily preventable with currently available tools. Vac-
cination is highly efﬁcacious for the pre-exposure prophylaxis (PrEP) of rabies in humans and animals,
and prompt postexposure prophylaxis (PEP) with vaccine and rabies immune globulin (RIG) can reliably
prevent disease in humans. However, access to these tools and knowledge of their proper use are often
limited, especially in impoverished, rabies-enzootic countries with the highest disease burden. In the
absence of reliable diagnostic capacity and risk assessments, vaccines and RIG are often administered
inappropriately, leading to chronic supply shortages and otherwise preventable deaths. Rather than
focusing solely on human prophylaxis, it is more cost-effective over the long term to eliminate canine
rabies in its natural terrestrial reservoirs. Because more than 99% of human rabies deaths result from
dog bites, prevention efforts should focus on dogs. A versatile ‘‘One Health’’ strategy for canine rabies
elimination should aim to create sustainable herd immunity in dogs, using proven vaccination strategies
at the local level, coupled with community education and humane population management. Such strat-
egies have succeeded in both developed and developing countries, and can be adapted to any locality.
Numerous examples in Africa, Asia, and Latin America have shown that community-based, locally guided
vaccination and education programs, based on a shared vision and long-term commitment, can eliminate
canine rabies. Such programs should have speciﬁc goals and measurable outcomes, and should be con-
ducted under the guidance of supportive governments, in collaboration with international partners
and nongovernmental organizations. In addition to currently available tools, rabies prevention can be
augmented by new dose-sparing human vaccine schedules, alternative routes of vaccine administration,
monoclonal antibodies as an alternative to RIG, sensitive and speciﬁc point-of-care diagnostics and the
development of canine immunocontraceptive methods. Accurate risk assessments of potential human
exposures and support for decentralized laboratory capacity will be essential to ensure the most effective
utilization of vaccines and RIG until canine rabies has been eliminated.
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Almost all human rabies deaths worldwide result from dog
bites. Most occur in Africa and Asia, where millions of exposures
occur annually, and more than 50,000 people die each year as a re-
sult of the local unavailability of postexposure prophylaxis (PEP)
with vaccine and rabies immune globulin (RIG) (Knobel et al.,
2005). Even when these biologics are available, educational gaps
or the absence of national recommendations may lead to their inef-
fective use (Folb and Cooke, 2007; Wilde, 2007).
Despite its global public health burden, canine rabies could
potentially be eliminated from the human population in the next
decades, since all of the necessary tools have been developed, val-
idated and used in some form in speciﬁc parts of the world. Unfor-
tunately, only rarely have all the tools been used in programs
implemented in coordination at the same time and location.
Achieving elimination will require governments, political leaders,
local communities, international partners, subject-matter experts
and non-governmental organizations (NGOs) to embrace a shared
vision, commit to a long-term strategy and work together to imple-
ment existing prophylactic and control measures (Hampson et al.,
2011; Lembo et al., 2011; Lembo and Partners for Rabies, 2012;
Wilde et al., 2012). The prevention and control of emerging zoono-
ses requires cooperation among animal and human health sectors,
ministries of education, local communities, international partners
and NGOs (Arambulo, 2011; Batsukh et al., 2012; Wright et al.,
2008). Success in eliminating canine rabies will therefore require
a coordinated, integrated, interdisciplinary ‘‘One Health’’ approach
(Briggs, 2012).
Creating a sustainable and successful rabies prevention pro-
gram requires strategic planning and the carefully orchestrated
spatiotemporal distribution of interventions for both humans and
animals (Rupprecht and Slate, 2012). Extensive experience in
industrialized countries and ongoing programs in Latin America,
Africa, and Asia have demonstrated that the elimination of canine
rabies is an achievable goal (Kamoltham et al., 2003a; Lembo et al.,
2010; Schneider et al., 2011). All of these programs have had strong
political support and have utilized a coordinated, evidence-based,
community-oriented multidisciplinary approach. They have also
avoided implementing one-sided strategies such as reliance on
PEP without proper risk assessment, which is too costly and does
not impact the source; indiscriminate dog culling without vaccina-
tion, which is unethical and ineffective; and canine vaccination
without population management, which is unsustainable (Morters
et al., 2013; Schneider et al., 2011; WHO, 2010).2. Current opportunities and challenges for rabies elimination
2.1. Prevention of rabies in humans
In most countries where canine rabies is enzootic, control mea-
sures, supplies of vaccine and RIG, routine interventions, relevant
recommendations and educational programs are either nonexis-
tent or inoperative. The lack of effective educational outreach at
the community level has led to gaps in knowledge as to the best
way to avoid animal bites and administer ﬁrst aid following bites
or other potential rabies exposures. Inadequate education for
veterinarians and physicians, insufﬁcient resources for proper
conﬁrmatory diagnosis and risk assessment, and the lack of effec-
tive communication channels between ministries of health and
agriculture frequently lead to failures of prophylactic intervention,
even in regions where biologics are available.
One health approach with massive canine vaccination programs
and widespread immunization of humans in the past few decades
have signiﬁcantly reduced the number of human rabies deaths inindustrialized countries and many urbanized areas of developing
countries (Fig. 1) (Hemachudha, 2005; Schneider et al., 2011;
WHO, 2010). While both approaches are needed, the ratio of dog
vaccination to human prophylaxis varies from country to country,
and is largely based on the availability of biologics. Countries with
higher gross domestic product or that produce their own effective
vaccines are generally able to implement both approaches (Davlin
and Vonville, 2012).
The most widely used biologics for human rabies prevention are
cell-culture and chick- or duck-embryo vaccines, which are highly
effective for rabies pre-exposure prophylaxis (PrEP) or PEP, when
used according to World Health Organization (WHO) recommen-
dations (WHO, 2005, 2010). PrEP is recommended by WHO as well
as ACIP (US Advisory Committee on Immunization Practices) for
laboratorians, veterinarians and animal control personnel, as well
as for people in remote regions who are at a high risk of rabies,
but have limited access to PEP. PrEP currently consists of a 3-dose
series of injections, that are most often administered intramuscu-
larly (IM) on days 0, 7, and 21 or 28 (Manning et al., 2008;
Rupprecht et al., 2010; WHO, 2010).
Three regimens are currently recommended for PEP following
exposure to a rabid or potentially rabid animal (Table 1). The re-
duced, 4-dose Essen, Zagreb and ACIP regimens, used predomi-
nantly in Europe, the Americas, some African countries, Australia
and the majority of Asian countries, are administered IM. The Thai
Red Cross modiﬁed intradermal (ID) dose-sparing regimen is used
on a regular basis in Thailand and the Philippines, and is slowly
being introduced in India, Sri Lanka and other developing countries
(Khawplod et al., 2007, 2012; Quiambao et al., 2005; Sudarshan
et al., 2010, 2012; Warrell, 2012).
2.2. Prevention and control of canine rabies
Parenteral vaccination of dogs is the most effective method of
preventing rabies in humans. Government- or NGO-sponsored
mass vaccination campaigns, or the mandatory vaccination of
owned dogs, has led to signiﬁcant decreases in human rabies in
many countries (Davlin and Vonville, 2012; Gongal and Wright,
2011; Kasempimolporn et al., 2008a; Schneider et al., 2007; Takay-
ama, 2000). The WHO has recommended that a successful canine
vaccination program should achieve at least 70% coverage of
canine population (Davlin and Vonville, 2012; Kasempimolporn
et al., 2008b; Schneider et al., 2007; Touihri et al., 2011). Given
the high reproductive rates of dogs, their short life span and an
age distribution that is often skewed towards a younger population
in developing or impoverished countries, it is challenging to
achieve effective long-term vaccination coverage (Davlin and
Vonville, 2012; WHO, 2010).
Programs of canine rabies control often devote more energy to
mass vaccination than to population management. However, some
regions of India and Latin America have successfully used
programs of spaying and neutering or animal birth control (ABC),
combining surgical sterilization with rabies vaccination, to manage
their dog populations (Totton et al., 2010). The ABC approach may
be quite challenging and costly. According to some ﬁeld studies
and population demographic models, almost 90% of free-roaming
dogs must be sterilized and vaccinated for vaccine coverage to
remain above 70%, and to achieve a stable 70% reduction in the
dog population within 13–18 years (Totton et al., 2010). Less than
40% surgical sterilization coverage would only maintain the dog
population at its original level (Totton et al., 2010).
Another option for canine population management is chemical
sterilization of male dogs, which has been used in Mexico, Brazil
and other countries (Jana and Samanta, 2007; Oliveira et al.,
2012; Soto et al., 2009). However, sterilization efforts should not
focus only on males, as females are also critical target for effective
Fig. 1. One Health approach to canine rabies elimination (PrEP – pre-exposure prophylaxis, PEP – post-exposure prophylaxis). Implementation of various primary and
secondary interventions lead to decrease in the number of people as well as dogs at the risk of rabies exposure and infection and ultimately to decrease in cases of animal and
human rabies.
Table 1
Pre- and postexposure regimens for ID or IM vaccination currently recommended by

















Routine 3 3 IDa 0, 7, 21 or 28
IMa,b
Post-exposure
Essen 5 5 IMa,b 0, 3, 7, 14, 28
Zagreb 4 3 IMa,b 0 (2 doses in each
deltoid)
7, 21
Reduced 4-dose 4 4 IMb 0, 3, 7, 14
Modiﬁed Thai
Red Cross
8 5 IDa (2 doses on each
day)
0, 3, 7, 28
Post-exposure for previously vaccinated persons
Two-dose 2 2 IMa,b 0, 3
Four-dose 4 1 IDa (2 doses above
each deltoid)
0
a Regimens recommended by WHO.
b Regimens recommended by ACIP.
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and Rowan, 2010). More often, however, rabies control programshave attempted to cull dog populations, even though this approach
has been shown to be ineffective (Dalla Villa et al., 2010; Johansen
and Penrith, 2009; Morters et al., 2013; Rupprecht et al., 2006).
Such lethal management strategies require the elimination of
50–80% of dogs a year, which is neither ﬁnancially possible nor
ethically acceptable (Rupprecht et al., 2002).
3. Future strategies for rabies prevention
3.1. Prevention of human rabies
As shown in Fig. 1, most cases of human rabies can be prevented
by eliminating the disease in dogs, through a combination of
Rupprecht et al. (2008), Wunner and Briggs (2010):
 appropriate risk-assessment programs, including laboratory
conﬁrmation or 10–14 day observation of animals causing a
bite injuries or other potential exposures;
 evidence-driven selective administration of modern prophylac-
tic tools;
 educational outreach; and
 sustainable programs of canine vaccination and population
management.
Nevertheless, the lack of availability of rabies biologics in
endemic countries has been a long-standing issue. The absence of
data on the burden of rabies and the lack of education reaching
the general public and health professionals on rabies prevention
R. Franka et al. / Antiviral Research 100 (2013) 220–225 223measures have also contributed to the neglected status of the dis-
ease and the large number of potentially preventable deaths
worldwide.
Political will is crucial for any sustainable disease prevention
program. When there are many competing interests, gaining the
attention of government will require accurate measurement of
the disease burden, but because most endemic countries lack lab-
oratory capacity as well as surveillance systems, their rabies bur-
den has not been adequately quantiﬁed (Dodet et al., 2010;
Knobel et al., 2005; Lembo et al., 2010). Efforts to eliminate rabies
must begin by building laboratory capacity and quantifying disease
rate, to permit the design of appropriate interventions and mea-
sure their impacts (Banyard et al., 2013).
Educational outreach and community engagement are critical
requirements for successful rabies control programs, but they are of-
ten neglected (Dodet et al., 2008). Even though avoiding exposure to
rabid animals is the most effective and inexpensive way to prevent
human rabies, this strategy is often overlooked, and communities
are frequently unaware of it. Breaking the vicious cycle of indiffer-
ence and lack of information should be a priority of rabies preven-
tion (Dodet et al., 2010). Given that most exposures and rabies
cases are in children under 15, educational outreach at the family le-
vel is especially important (Hampson et al., 2008). Population sur-
veys focusing on rabies prevention have repeatedly identiﬁed gaps
in knowledge of risks,modes of transmission, avoidance of exposure
and preventive measures (Altmann et al., 2009; Ichhpujani et al.,
2006; Mai le et al., 2010; Matibag et al., 2007; Robertson et al.,
2011). To build and strengthen health-promoting habits, effective
rabies prevention requires changes in community health-seeking
behaviors, including the avoidance of rabies exposures, immediate
washing of biteswith soap andwater, and consultationwith a public
health professional after any animal bite.
Continuing education of physicians, veterinarians and other
health professionals will ensure inter-sectoral coordination and
communication on the local, national and international levels. By
means of World Rabies Day events, the Global Alliance for Rabies
Control (GARC) and other members of the Partners for Rabies Pre-
vention (PRP) motivate and enable thousands of professionals and
enthusiasts worldwide to educate people in their communities.
GARC is reaching hundreds of thousands people annually with
webinars and other electronic media (http://www.worldrabies-
day.org/).
Successful rabies prevention programs rely on the engagement
and empowerment of local communities (Kaare et al., 2009; Sin-
tunawa et al., 2004). Implementation of lessons about the preven-
tion of rabies and other zoonotic diseases in the school
curriculum may signiﬁcantly reduce dog bites and human rabies
cases. This approach has been successfully implemented using
the constructionist theory of experiential learning (‘‘learning
through play’’), in which children do not just passively receive
knowledge, but actively construct meaning (Agonnoude and Mes-
enge, 2010). The engagement of religious leaders and their com-
munities is another effective approach. Provision of community
leaders with culturally appropriate information, training, and pro-
motion of skill-building activities may create a ‘‘ripple effect’’ of
knowledge of rabies and its prevention as seen with other suc-
cessful disease programs (Gore et al., 2012). Such educational
outreach may decrease the number of rabies exposures, through
avoidance of stray animals, and increase proper wound care by
washing with soap and water, and through consultation and pro-
phylaxis-seeking behavior. However, once a true exposure to a ra-
bid animal has occurred, a modern cell-culture vaccine and RIG
must be administered in accordance with WHO, ACIP or other na-
tional recommendations (Briggs, 2012; Rupprecht et al., 2010;
WHO, 2010).The pipeline for the development and production of new rabies
biologics is decades long, and most rabies-endemic countries do
not have local vaccine manufacturers, or have only a limited pro-
duction capacity. Because human rabies vaccines are in the short-
est supply in countries with the greatest need, new routes of
administration, shortened schedules and dose-sparing regimens
will need to be made available for communities in endemic coun-
tries. The Modiﬁed Thai Red Cross ID regimen is an ideal dose-spar-
ing alternative to IM administration, which is recommended by the
WHO and widely used in Thailand and the Philippines, and to a les-
ser extent in other Asian countries (Table 1). Because ID adminis-
tration reduces the volume of vaccine required for PEP by as
much as 80%, its use would be crucial where the vaccine supply
is limited (Kamoltham et al., 2003b). However, because of its pro-
longed dosing schedule, the currently recommended ID regimen
has sometimes led to poor compliance. A new one-week ID regi-
men (4-4-4, on day 0, 3 and 7) was therefore developed and is
being evaluated in pilot studies in Thailand and India (Shan-
tavasinkul et al., 2010; Sudarshan et al., 2012). Similar attempts
to minimize the number of PrEP vaccine doses have also been ini-
tiated, and preliminary data suggest that a single full IM dose, or
two 0.1 mL ID injections on one day, are adequate to prime im-
mune memory and to obtain an accelerated immune response
one year later (Khawplod et al., 2012).
Recent research on improved vaccine delivery has focused on
the development and clinical evaluation of new devices for more
reliable needle-free delivery, to reduce or eliminate needlestick
injuries and the costs associated with their treatment. ID delivery
devices such as microneedle patches are also being considered
for future evaluation. Such patches may occupy less volume than
vials or preﬁlled syringes, reducing demands on cold-chain capac-
ity (Hickling et al., 2011). The inclusion of rabies PrEP in scheduled
pediatric immunization for high-risk populations, when there are
no better alternatives, is also garnering increased consideration
(Lang et al., 2009; Shanbag et al., 2008). Multiple studies have
demonstrated that the administration of PrEP to school-aged chil-
dren is safe and feasible, and brings signiﬁcant beneﬁt to the com-
munity by providing long-term immunity and preventing deaths
(Dodet et al., 2010).
Although human or equine rabies immune globulins (RIG) are
an essential part of PEP, providing passive immunity until an im-
mune response to vaccination has developed, they are frequently
unavailable in resource-poor countries. A major barrier to wider
access to these products is the need for human or animal plasma
donors. New manufacturing practices and technologies to produce
large quantities of ‘‘cocktails’’ of selected monoclonal antibodies
may provide an alternative in the near future, expanding their
availability throughout the world (Bakker et al., 2008; de Kruif
et al., 2007; Gogtay et al., 2012; Goudsmit et al., 2006; Muller
et al., 2009; Smith et al., 2011).
In addition to ensuring the availability of rabies biologics, there
is also an urgent need to establish laboratory capacity and national
risk assessment systems in regions where surveillance is limited or
non-existent (Banyard et al., 2013; Briggs, 2012). Diagnostic and
surveillance systems will provide the critical information to facili-
tate decision making regarding the need for PEP in cases of expo-
sure to potentially rabid animals. Policy makers and health care
professionals will also make use of reliable epidemiological data
to design and implement the most appropriate and cost-efﬁcient
preventive measures for their situations (Fig. 1).
3.2. Prevention and control of canine rabies
The elimination of canine rabies is the most cost-effective long-
term intervention to prevent the disease in humans. A combination
of parenteral vaccination and population management of
224 R. Franka et al. / Antiviral Research 100 (2013) 220–225free-ranging dogs, through surgical or chemical sterilization or
capture and euthanasia, can successfully prevent rabies, provided
the vaccination coverage approaches 70% and the dog population
stabilizes or decreases (Lembo et al., 2012; Morters et al., 2013;
Totton et al., 2010). Unfortunately, in many parts of the world,
overpopulation is handled by culling, which is unethical and has
only a transient impact (Jackman and Rowan, 2010; Morters
et al., 2013).
Because of their intrinsic interconnections, public health, envi-
ronmental protection and animal welfare are all improved by ca-
nine rabies vaccination and mass sterilization programs. The
development of techniques to efﬁciently deliver rabies prevention
and population control on a broad scale, with minimal technical
requirements and low costs, is therefore imperative. Multiple sin-
gle-injection methods for simpliﬁed population control in males,
females or both genders are currently being evaluated. For exam-
ple, Gonazon is a contraceptive that contains the active substance
azagly-nafarelin; if used as an implant in female or male dogs, it
prevents gonadal function via long-term blockage of gonadotro-
phin synthesis (Goericke-Pesch et al., 2010; Ludwig et al., 2009).
GonaCon (APHIS/USDA), a synthetic gonadotrophin-releasing
hormone (GnRH) coupled to keyhole limpet hemocyanin and com-
bined with a novel adjuvant, has been shown to suppress testoster-
one and estrogen production and reduce fertility in both genders in
species such as deer and pigs, and induce high anti-GnRH antibod-
ies in squirrels, rabbits, rodents, coyotes, horses, and bison, follow-
ing a single dose (Killian et al., 2009; Miller et al., 2008). When
GonaCon was administered to dogs together with rabies vaccine,
no interference with immune responses was observed (Bender
et al., 2009).
Several studies have conﬁrmed the efﬁcacy of the GnRH peptide
as an immunocontraceptive in both genders of various animal
species. It has therefore been proposed that GnRH could be admin-
istered together with rabies vaccine in a dual immunocontracep-
tive vaccine, which would serve as a humane, ethical and highly
efﬁcacious means of both controlling dog populations and protect-
ing against rabies (Wu et al., 2009). In preliminary experiments,
three doses of the live or inactivated recombinant virus ERAg3p/
2GnRH induced sufﬁcient titers of anti-rabies antibodies and
P80% level of immunocontraception in mice (Wu et al. unpub-
lished data). If administered IM or orally in a mass vaccination
campaign, such a vaccine would render animals of both genders
both infertile and immune to rabies. However, one concern for
acceptance of such a product is whether it is able to prevent estrus
and its associated negative behavior, such as wandering and
aggression among potential mates. The principal advantage of a
dual rabies/immunocontraceptive vaccine is that it might be suit-
able for oral administration, allowing its administration via bait.
By avoiding the need for animal capture, this would provide an
enormous advantage for oral rabies vaccination and sterilization
of free-ranging dog populations. Vaccines against GnRH would also
have the advantage of suppressing sexual behavior in stray males
and females (Kutzler and Wood, 2006).
Although novel approaches and more efﬁcacious and accessible
tools for rabies management are being developed and evaluated,
proven tools are already abundantly available. If used wisely in
coordinated, community-based, evidence-driven One Health ap-
proaches (Fig. 1), these tools will make possible the global elimina-
tion of canine rabies and the prevention of almost all human rabies
deaths in the future.Acknowledgements
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